Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, presents new po...
Read moreUna serie de artículos publicados en diferentes revistas del grupo CellPress resume el conocimiento sobre la biología de los viajes espaciales que se ha obtenido durante las últimas décadas. Los a...
Read moreUn equipo de investigadores de la Universidad de Exeter, en Reino Unido, ha elaborado un “reloj epigenético” para estimar la edad biológica del cerebro. Este método, basado en las marcas epigen...
Read more El colangiocarcinoma es un tipo de cáncer que se desarrolla en las vías biliares, conductos que conectan el hígado con la vesícula biliar y con el intestino delgado. Se trata de una enferme...
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announce...
Read moreA single tumour, or even a single cancer cell, can present multiple genetic alterations at the same time: point mutations, lose or gain of specific genetic fragments, among others. Understanding how t...
Read moreBoth plants and animals can regulate patterning through developmental clocks that involve oscillating gene expression.
Read moreEl Cima Universidad de Navarra participa en una investigación que identifica alteraciones epigenéticas en este tumor hematológico y demuestra la eficacia de un compuesto que las revierte
Read moreThe objective of RENACER is to carry out basic and clinical studies that help to advance the development of therapies for these metastases With prior consent from the patients, surgeons will collec...
Read moreResearchers at the CNIC have discovered that dendritic cells, which initiate specific immune responses, can reprogram their genes to improve their immune response
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announce...
Read moreCarried out in collaboration with investigators at the Policlinico in Milan, VHIO, Vall d’Hebron University Hospital (HUVH) – Vall d’Hebron Research Institute (VHIR), Barcelona, and the Universi...
Read more